Novo Nordisk Annual Report 2021

Contents Introducing Novo Nordisk Strategic Aspirations Key risks Management Consolidated statements Additional information. Novo Nordisk Annual Report 2021 27 O+ C Pipeline overview Diabetes care Biopharm Phase Type 2 diabetes Type 1 and Project Indication Semaglutide 2.0 mg NN9535 Type 2 diabetes Oral semaglutide HD¹ NN9924 Icodec NN1436 2 diabetes Icosema NN1535 Type 2 diabetes FDC Sema - OW GIP NN9389 CagriSema in T2D NN9388 Type 2 diabetes Type 2 diabetes Insulin 965 NN1965 Type 1 and 2 diabetes Glucose-sensitive insulin Type 1 and NN1845 Ideal Pump Insulin NN1471 2 diabetes Type 1 diabetes Description A long-acting GLP-1 analogue for once-weekly treatment. A long-acting oral GLP-1 analogue, 25 and 50 mg, intended for once-daily oral treatment. A long-acting basal insulin analogue intended for once-weekly treatment. A combination of GLP-1 analogue semaglutide and insulin icodec intended for once-weekly treatment. A combination of semaglutide and novel GIP intended for once-weekly treatment. A combination of amylin analogue and GLP-1 analogue semaglutide intended for once-weekly treatment. A novel basal insulin analogue intended for once-daily treatment. A glucose-sensitive insulin analogue intended for once-daily treatment. A novel insulin analogue ideal for use in a closed loop pump device as delivery. A novel plasmid encoding pre- and pro-insulin intended for preservation of beta cell function. A long acting GLP-1 analogue intended for once-daily treatment. Phase Project Sogroya® NN8640 Somapacitan NN8640 Concizumab NN7415 Macimorelin EX2020 Mim8 NN7769 Nedosiran? Eclipse NN7533 Indication Adult GHD² GHD2 Haemophilia A and B w/wo inhibitors GHD2 Haemophilia A with or without inhibitors Primary Hyperoxaluria Sickle cell disease Other serious chronic diseases Semaglutide³ Ziltivekimab NN6018 Belcesiran Description A long-acting HGH³ derivative intended for once-weekly subcutaneous administration in adults.. A long-acting HGH³ derivative intended for once- weekly subcutaneous administration in children. A monoclonal antibody against tissue factor pathway inhibitor (TFPI) intended for subcutaneous prophylaxis treatment. An oral diagnostic agent used for the diagnosis of GHD in adolescents and children. A next generation FVIII mimetic bispecific antibody for subcutaneous prophylaxis of haemophilia A regardless of inhibitor status. An siRNA targeting lactate dehydrogenase A (or LDHA) for once monthly subcutaneous treatment. An oral combination treatment of sickle cell disease and beta thalassaemia. Project is developed in collaboration with EpiDestiny. A long-acting GLP-1 analogue for once-weekly treatment of NASH4. A long-acting GLP-1 analogue for once-daily treatment of Alzheimer's disease. A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity. An siRNA targeting Alpha-1-AntiTrypsin (AAT) for once monthly subcutaneous treatment. NASH4 DNA Immunotherapy NN9041 Type 1 NN9931 diabetes Semaglutide Alzheimer Alzheimer's NN6535 Obesity care CVD5 Oral Sema Obesity Obesity NN9932 AATD6 PYY1875 Obesity NN9775 A novel analogue of the appetite-regulating hormone, PYY, intended for once-weekly treatment. Oral PCSK9i NN6435 CVD5 A long-acting PCSK9 inhibitor for oral treatment. Cagrilintide Obesity NN9838 A novel long-acting amylin analogue intended for once-weekly treatment. FGF-21 NASH NASH4 NN9500 A long-acting FGF21 analogue for once-weekly treatment of NASH. CagriSema Obesity NN9838 LA-GDF15 Obesity NN9215 A combination of amylin analogue cagrilintide and GLP-1 analogue semaglutide intended for once-weekly treatment. A long-acting GDF15 analogue intended for appetite regulation leading to weight loss. PRX004 CVD5 NN6019 DCR-AUD7 Alcohol Use Disorder An anti-amyloid immunotherapy treatment for ATTR5. An siRNA targeting ALDH2 for once monthly subcutaneous treatment. 2020 2021 O O O Phase 1 ○ ○ Phase 2 ○ Phase 3 Submission and/or approval 1. High dose 2. GHD: Growth hormone deficiency 3. HGH: Human growth hormone 4. NASH: Non-alcoholic steatohepatitis 5. CVD: Cardiovascular disease 6. Alpha-1-AntiTrypsin Deficiency related liver disease 7. Asset without NN project ID 8. This project also includes a phase 2b study in F4 in a collaboration with Gilead

View entire presentation